BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 2108114)

  • 21. Mechanism for synergism between sulphonamides and trimethoprim clarified.
    Richards RM; Taylor RB; Zhu ZY
    J Pharm Pharmacol; 1996 Sep; 48(9):981-4. PubMed ID: 8910868
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Promoter strength of folic acid synthesis genes affects sulfa drug resistance in Saccharomyces cerevisiae.
    Iliades P; Berglez J; Meshnick S; Macreadie I
    Microb Drug Resist; 2003; 9(3):249-55. PubMed ID: 12959403
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Wet disc testing of mafenide hydrochloride, chlorhexidine gluconate, and triple antibiotic solution against bacteria isolated from burn wounds.
    Holder IA
    J Burn Care Rehabil; 1990; 11(4):301-4. PubMed ID: 2401684
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of dihydropteroate synthetase from Escherichia coli by sulfones and sulfonamides.
    McCullough JL; Maren TH
    Antimicrob Agents Chemother; 1973 Jun; 3(6):665-9. PubMed ID: 4597736
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 8-Mercaptoguanine Derivatives as Inhibitors of Dihydropteroate Synthase.
    Dennis ML; Lee MD; Harjani JR; Ahmed M; DeBono AJ; Pitcher NP; Wang ZC; Chhabra S; Barlow N; Rahmani R; Cleary B; Dolezal O; Hattarki M; Aurelio L; Shonberg J; Graham B; Peat TS; Baell JB; Swarbrick JD
    Chemistry; 2018 Feb; 24(8):1922-1930. PubMed ID: 29171692
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Quantitative structure-activity relationships in dihydropteroate synthase inhibition by multisubstituted sulfones. Design and synthesis of some new derivatives with improved potency.
    De Benedetti PG; Iarossi D; Folli U; Frassineti C; Menziani MC; Cennamo C
    J Med Chem; 1989 Oct; 32(10):2396-9. PubMed ID: 2677378
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Crystal structure of Mycobacterium tuberculosis 7,8-dihydropteroate synthase in complex with pterin monophosphate: new insight into the enzymatic mechanism and sulfa-drug action.
    Baca AM; Sirawaraporn R; Turley S; Sirawaraporn W; Hol WG
    J Mol Biol; 2000 Oct; 302(5):1193-212. PubMed ID: 11007651
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of Plasmodium falciparum dihydropteroate synthetase and growth in vitro by sulfa drugs.
    Zhang Y; Meshnick SR
    Antimicrob Agents Chemother; 1991 Feb; 35(2):267-71. PubMed ID: 2024960
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Crystal structure of the anti-bacterial sulfonamide drug target dihydropteroate synthase.
    Achari A; Somers DO; Champness JN; Bryant PK; Rosemond J; Stammers DK
    Nat Struct Biol; 1997 Jun; 4(6):490-7. PubMed ID: 9187658
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Toxoplasma gondii: characterization of a mutant resistant to sulfonamides.
    Pfefferkorn ER; Borotz SE; Nothnagel RF
    Exp Parasitol; 1992 May; 74(3):261-70. PubMed ID: 1582478
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Computational insights into factor affecting the potency of diaryl sulfone analogs as Escherichia coli dihydropteroate synthase inhibitors.
    Das BK; Pv P; Chakraborty D
    Comput Biol Chem; 2019 Feb; 78():37-52. PubMed ID: 30497019
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dihydropteroate synthase mutations in Pneumocystis jiroveci can affect sulfamethoxazole resistance in a Saccharomyces cerevisiae model.
    Iliades P; Meshnick SR; Macreadie IG
    Antimicrob Agents Chemother; 2004 Jul; 48(7):2617-23. PubMed ID: 15215118
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of a class of sulfonamides highly active against dihydropteroate synthase form Toxoplasma gondii, Pneumocystis carinii, and Mycobacterium avium.
    Chio LC; Bolyard LA; Nasr M; Queener SF
    Antimicrob Agents Chemother; 1996 Mar; 40(3):727-33. PubMed ID: 8851601
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mafenide (Sulfamylon) inhibits plasmin fibrinolytic activity.
    Weisdorf DJ; Aldridge JH
    Thromb Haemost; 1988 Jun; 59(3):440-4. PubMed ID: 2973151
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The characteristics and significance of sulfonamides as substrates for Escherichia coli dihydropteroate synthase.
    Roland S; Ferone R; Harvey RJ; Styles VL; Morrison RW
    J Biol Chem; 1979 Oct; 254(20):10337-45. PubMed ID: 385600
    [No Abstract]   [Full Text] [Related]  

  • 36. Arabidopsis dihydropteroate synthase: general properties and inhibition by reaction product and sulfonamides.
    Prabhu V; Lui H; King J
    Phytochemistry; 1997 May; 45(1):23-7. PubMed ID: 9127492
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dihydropteroate synthase from Streptococcus pneumoniae: structure, ligand recognition and mechanism of sulfonamide resistance.
    Levy C; Minnis D; Derrick JP
    Biochem J; 2008 Jun; 412(2):379-88. PubMed ID: 18321242
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cell-free dihydropteroate synthetase activity: its use to investigate the relationship between structure and activity of p-aminobenzoic derivatives.
    Thijssen HH
    Methods Enzymol; 1980; 66():570-6. PubMed ID: 6990197
    [No Abstract]   [Full Text] [Related]  

  • 39. Evaluation of sulfa drugs against recombinant Pneumocystis carinii dihydropteroate synthetase and in vivo.
    Hong YL; Hossler P; Bartlett M; Queener S; Smith J; Meshnick S
    J Eukaryot Microbiol; 1996; 43(5):40S. PubMed ID: 8822843
    [No Abstract]   [Full Text] [Related]  

  • 40. Sulfonamide resistance mechanism in Escherichia coli: R plasmids can determine sulfonamide-resistant dihydropteroate synthases.
    Wise EM; Abou-Donia MM
    Proc Natl Acad Sci U S A; 1975 Jul; 72(7):2621-5. PubMed ID: 1101260
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.